{"id":"nucleotidic-or-nucleosidic-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Mitochondrial toxicity / lactic acidosis"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Gastrointestinal disturbance"}]},"_chembl":{"chemblId":"CHEMBL5970128","moleculeType":null,"molecularWeight":"607.73"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This class of antivirals works by mimicking natural nucleotides or nucleosides and becoming incorporated into viral nucleic acid synthesis, causing chain termination or preventing proper viral enzyme function. These agents are commonly used against HIV and hepatitis B virus, targeting the viral reverse transcriptase or polymerase enzymes essential for viral replication.","oneSentence":"Nucleotidic or nucleosidic compounds inhibit viral reverse transcriptase and/or other viral enzymes to suppress replication of retroviruses or other nucleic acid-dependent pathogens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:31.065Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV infection (as part of combination antiretroviral therapy)"},{"name":"Hepatitis B virus infection"}]},"trialDetails":[{"nctId":"NCT01172392","phase":"PHASE3","title":"A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-01","conditions":"Chronic Hepatitis B, AgHbs Negativation","enrollment":185}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1134756,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Nucleotidic or Nucleosidic Treatment","genericName":"Nucleotidic or Nucleosidic Treatment","companyName":"ANRS, Emerging Infectious Diseases","companyId":"anrs-emerging-infectious-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nucleotidic or nucleosidic compounds inhibit viral reverse transcriptase and/or other viral enzymes to suppress replication of retroviruses or other nucleic acid-dependent pathogens. Used for HIV infection (as part of combination antiretroviral therapy), Hepatitis B virus infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}